ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis

被引:80
|
作者
Thomassen, Mary Jane [1 ]
Barna, Barbara P.
Malur, Achut G.
Bonfield, Tracey L.
Farver, Carol F.
Malur, Anagha
Dalrymple, Heidi
Kavuru, Mani S.
Febbraio, Maria
机构
[1] E Carolina Univ, Dept Microbiol & Immunol, Div Pulm & Crit Care Med, Program Lung Cell Biol & Translational Res, Greenville, NC 27858 USA
[2] Cleveland Clin Fdn, Dept Pulm Allerg & Crit Care Med, Cleveland, OH USA
[3] Cleveland Clin Fdn, Dept Pathol Anat, Cleveland, OH USA
[4] Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH USA
关键词
liver X receptor alpha; peroxisome proliferatoractivated receptor gamma; ATP binding cassette transporter A1; ATP binding cassette transporter G1; foam cells; granulocyte-macrophage colony-stimulating factor;
D O I
10.1194/jlr.P700022-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Patients with pulmonary alveolar proteinosis ( PAP) display impaired surfactant clearance, foamy, lipidfilled alveolar macrophages, and increased cholesterol metabolites within the lung. Neutralizing autoantibodies to granulocyte-macrophage colony-stimulating factor ( GMCSF) are also present, resulting in virtual GM-CSF deficiency. We investigated ABCG1 and ABCA1 expression in alveolar macrophages of PAP patients and GM-CSF knockout ( KO) mice, which exhibit PAP-like pulmonary pathology and increased pulmonary cholesterol. Alveolar macrophages from both sources displayed a striking similarity in transporter gene dysregulation, consisting of deficient ABCG1 accompanied by highly increased ABCA1. Peroxisome proliferator-activated receptor gamma (PPAR gamma), a known regulator of both transporters, was deficient, as reported previously. In contrast, the liver X receptor a, which also upregulates both transporters, was highly increased. GMCSF treatment increased ABCG1 expression in macrophages in vitro and in PAP patients in vivo. Overexpression of PPARg by lentivirus-PPAR gamma transduction of primary alveolar macrophages, or activation by rosiglitazone, also increased ABCG1 expression. These results suggest that ABCG1 deficiency in PAP and GM-CSF KO alveolar macrophages is attributable to the absence of a GM-CSF-mediated PPAR gamma pathway. These findings document the existence of ABCG1 deficiency in human lung disease and highlight a critical role for ABCG1 in surfactant homeostasis.
引用
收藏
页码:2762 / 2768
页数:7
相关论文
共 50 条
  • [31] Occupational inhalational exposure and serum GM-CSF autoantibody in pulmonary alveolar proteinosis
    Xiao, Yong-Long
    Xu, Kai-Feng
    Li, Yan
    Li, Yan
    Li, Hui
    Shi, Bin
    Zhou, Ke-Feng
    Zhou, Zheng-Yang
    Cai, Hou-Rong
    OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2015, 72 (07) : 504 - 512
  • [32] LENTIVIRUS GM-CSF GENE THERAPY AMELIORATES AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS
    Lund-Palau, H.
    Meng, C.
    Pilou, A.
    Atsumi, N.
    Bhargava, A.
    Chan, M.
    Byrne, A.
    Pringle, I.
    Ashworth, R.
    Gill, D.
    Hyde, S.
    Morgan, C.
    Alton, E.
    Griesenbach, U.
    THORAX, 2018, 73 : A1 - A2
  • [33] Lentiviral vector/GM-CSF Gene Therapy for Autoimmune Pulmonary Alveolar Proteinosis
    Juarez-Molina, C. I.
    Lund-Palau, H.
    Meng, C.
    Gill, D.
    Hyde, S.
    Alton, E.
    Griesenbach, U.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A38 - A38
  • [34] Pulmonary Alveolar Proteinosis (PAP) Caused by GM-CSF Receptor α Defects.
    Suzuki, T.
    Sakagami, T.
    Rubin, B.
    Wood, R.
    Carey, B.
    Whitsett, J. A.
    Trapnell, B. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [35] Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis
    Ohashi, K.
    Sato, A.
    Takada, T.
    Arai, T.
    Kasahara, Y.
    Hojo, M.
    Nei, T.
    Nakayama, H.
    Motoi, N.
    Urano, S.
    Eda, R.
    Yokoba, M.
    Tsuchihashi, Y.
    Nasuhara, Y.
    Ishii, H.
    Ebina, M.
    Yamaguchi, E.
    Inoue, Y.
    Nakata, K.
    Tazawa, R.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 39 (03) : 777 - 780
  • [36] A Mechanism For Acceleration Of Gm-Csf Autoantibody Production In Autoimmune Pulmonary Alveolar ProteINOSis
    Nakata, K.
    Nei, T.
    Motoi, N.
    Urano, S.
    Tazawa, R.
    Nakagaki, K.
    Suzuki, M.
    Takizawa, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [37] NOVEL GM-CSF RECEPTOR MUTATION PRESENTING WITH PULMONARY ALVEOLAR PROTEINOSIS IN CHILDHOOD
    KUMAR, K.
    MATHEW, J. L.
    SINGH, M.
    SINGHAL, K. K.
    SINGH, S.
    GANTA, A. R.
    SODH, K. S., I
    GUPTA, N.
    BAL, A.
    MENON, P.
    CHEST, 2022, 161 (06) : 264A - 264A
  • [38] The dramatic therapeutic response to inhaled GM-CSF in severe pulmonary alveolar proteinosis
    Wu, Xian Georg
    Koller, Hubert
    Huber, M.
    Pattermann, Andreas
    Hartl, Sylvia
    Meilinger, Michael
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 (19-20) : 626 - 627
  • [39] BAL findings in a patient with pulmonary alveolar proteinosis successfully treatelwulith GM-CSF
    Schoch, OD
    Schanz, U
    Koller, M
    Nakata, K
    Seymour, JF
    Russi, EW
    Boehler, A
    THORAX, 2002, 57 (03) : 277 - 280
  • [40] Mechanisms For Excessive Production Of GM-CSF Autoantibody In Autoimmune Pulmonary Alveolar Proteinosis
    Nei, T.
    Urano, S.
    Kaneko, C.
    Motoi, N.
    Takizawa, J.
    Tazawa, R.
    Nakagaki, K.
    Akagawa, K.
    Trapnell, B.
    Nakata, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181